Drug Profile
Sildenafil sublingual - Kedem Pharmaceuticals
Alternative Names: GLV-0901; X-ExciteLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Global Health Ventures
- Developer Kedem Pharmaceuticals
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Erectile dysfunction
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Erectile-dysfunction in Europe (Sublingual)
- 07 Nov 2011 Global Health Ventures is now called Kedem Pharmaceuticals
- 22 Jun 2011 Pharmacokinetics data from a phase I trial in Erectile dysfunction released by Global Health Ventures